EE317 Cost-Effectiveness of Adjuvant Olaparib in Germline BRCA1/2-Mutated, High-Risk, Human Epidermal Growth Factor-2-Negative Early Breast Cancer: A Canadian Perspective. - Parackal, A; Ting, E; Verhoek, A; Joy, A; Sehdev, S; Hettle, R (Value in Health, 2024)